Ipca Labs receives approval for voluntary closure of wholly owned subsidiary in Mexico
Mumbai: Ipca Laboratories Limited has announced that the Company has received the necessary approval for the voluntary closure of its wholly owned subsidiary Ipca Pharmaceuticals Ltd SA de CV, Mexico. This wholly owned subsidiary incorporated in Mexico was not doing any business for the past several years.
"Voluntary closure of this wholly owned subsidiary will not have any impact on Company’s business or financials," the Company stated in a BSE filing.
Approval Letter dated 28th November, 2024 from Mexican authority received by the Company on 4th December, 2024
Read also: Ipca Labs net profit up 18 percent to Rs 192 crore in Q1
Established in 1949, lpca is a pharmaceutical company. lpca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients. For more than 70 years, lpca has been a crucial healthcare partner in over 120 countries across the globe. lpca markets its branded formulations in India and rest of the world markets and generic formulations in United States, Europe, United Kingdom, Canada, Australia & New Zealand. APls manufactured by lpca are marketed across the globe.
Read also: Ipca Labs enters into technology transfer agreement with Omexa Formulary
